[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351473-105":59,"doc-detail-351473-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","nebivolol-prevents-exhausted-t-cells-and-enhances-cytotoxicity-against-mcf-7-breast-cancer-cells-in-a-2-adrenergic-receptor-dependent-manner","Nebivolol prevents exhausted T cells and enhances cytotoxicity against MCF-7 breast cancer cells in a β2-adrenergic receptor-dependent manner","","Nebivolol reduces T cell exhaustion and improves anti-tumor cytotoxicity against MCF-7 breast cancer cells via a β2-adrenergic receptor mechanism. The study models exhaustion using repeated in vitro CD3/CD28/CD2 activation and measures inhibitory checkpoint markers (PD-1, TIM-3, CD38) and transcriptional regulators (TOX, NFATc1) with flow cytometry, RT-qPCR and western blot. Nebivolol increases TNF secretion and restores cytotoxic function; effects are lost with ADRB2 disruption, while β1 modulation does not block activity. Keywords cover T cell exhaustion, β2-adrenergic signaling, tumor microenvironment and cytotoxic T cells.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nebivolol-prevents-exhausted-t-cells-and-enhances-cytotoxicity-against-mcf-7-breast-cancer-cells-in-a-2-adrenergic-receptor-dependent-manner/351473/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nebivolol-prevents-exhausted-t-cells-and-enhances-cytotoxicity-against-mcf-7-breast-cancer-cells-in-a-2-adrenergic-receptor-dependent-manner/351473.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn Holloway","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does nebivolol affect T cell exhaustion markers?","Question",{"text":112,"@type":113},"Nebivolol reduces TIM-3+CD38+ PD-1+ T cells, downregulates TOX and nuclear NFATc1, and restores ADRB2 expression under repeated activation conditions.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Does nebivolol improve cytotoxicity against MCF-7 breast cancer cells?",{"text":117,"@type":113},"Yes. Nebivolol increases TNF secretion and improves cytotoxicity against MCF-7 cells in co-culture assays after repeated activation.",{"name":119,"@type":110,"acceptedAnswer":120},"Is nebivolol’s effect dependent on β1- or β2-adrenergic receptors?",{"text":121,"@type":113},"The effects are mediated through β2-AR. Metoprolol (β1-blocker) does not inhibit nebivolol’s activity, and CRISPR/Cas9 disruption of ADRB2 indicates β2-AR dependency.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351473,1790148958,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336474466712,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Nebivolol prevents exhausted T cells and enhances cytotoxicity against MCF-7 breast cancer cells in a β2-adrenergic receptor-dependent manner  \nMehri Hajiaghayi  1, Fatemeh Gholizadeh1, Niloufar Rahbari2, Negaralsadat Emamnia1, Steve C.C. Shih3 and Peter J. Darlington1,4*  \n1 Department of Biology, School of Health, Concordia University, Montréal, Québec, Canada  \n2 Department of Chemical and Materials Engineering, Center for Applied Synthetic Biology, Concordia University, Montréal, Québec, Canada 3 Department of Electrical and Computer Engineering, School of Health, Concordia University, Montréal, Québec, Canada  \n4 Department of Health Kinesiology & Applied Physiology, School of Health, Concordia University, Montréal, Québec, Canada  \n*Corresponding author. Peter J. Darlington, Concordia University, Loyola Campus, SP165 .41 – 7141 Sherbrooke Street W., Montréal, Québec H4B 1R6, Canada. Email: [peter.darlington@concordia.ca](peter.darlington@concordia.ca)  \nAbstract  \nIntroduction Cancers often drive T cells toward an exhausted state characterized by impaired cytotoxicity and upregulation of inhibitory receptors (PD-1, TIM-3, CD38) and transcriptional regulators (TOX, NFATc1). Repeated stimulation in vitro is used to model this process, reflecting chronic antigen exposure in the tumor microenvironment. Stress-derived catecholamines further drive dysfunction through β-adrenergic receptor (β-AR) signaling. Here, we examined the impact of nebivolol, an atypical β1-AR blocker with β2-biased agonist activity, on T-cell exhaustion and cytotoxicity against breast cancer cells.  \nMethods Human CD3+ T cells from healthy participants were activated once (early activation) or four times (repeated activation) using CD3/CD28/CD2 T cell activator. Cells were treated in vitro with nebivolol, terbutaline (β2-agonist), isoproterenol (β1/β2-agonist), and metoprolol (β1-blocker). Exhaustion markers, including PD-1, TIM-3, CD38, and TOX, were measured by flow cytometry and RT-qPCR; NFATc1 by western blot; TNF and IFN-γ by ELISA, and cytotoxicity against MCF-7 breast carcinoma cells by co-culture assays. Disruption of the β2-AR gene (ADRB2) was achieved using CRISPR/Cas9.  \nResults Nebivolol reduced the proportion of TIM-3+CD38+ PD-1+ T cells, downregulated TOX and nuclear NFATc1, and restored ADRB2 expression under repeated activation conditions. Nebivolol enhanced TNF secretion and improved cytotoxicity against MCF-7 cells. In contrast, terbutaline and isoproterenol had no significant effect on exhaustion markers or cytotoxicity. Metoprolol did not inhibit nebivolol’s activity, indicating that its effects are not β1-ARdependent. Disruption of ADRB2 indicated that nebivolol’s anti-exhaustion effects are mediated by β2-AR.  \nDiscussion These findings show that nebivolol reinvigorates CD4+ and CD8+ T cells following repeated activation, restoring their cytotoxic function against breast cancer cells in vitro. The immunomodulatory activity of Nebivolol is independent of β1-AR and mediated through β2-AR, suggesting that biased β2-AR signaling may represent a potential strategy for modulating T cell exhaustion in the tumor microenvironment.  \nKeywords T cell exhaustion, β2-adrenergic receptors, nebivolol, tumor microenvironment, cytotoxic T cells  \nAbbreviations: β-AR: β-adrenergic receptor; β1-AR: β1-adrenergic receptor; β2-AR: β2-adrenergic receptor; ADRB2: adrenergic receptor beta 2 gene; CAR: chimeric antigen receptor; CFDA-SE: carboxyfluorescein diacetate N-succinimidyl ester; CRISPR: clustered regularly interspaced short palindromic repeats; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; IFN-γ: interferon gamma; NFAT: nuclear factor of activated T cells; NFATc1: nuclear factor of activated T cells c1; PBMCs: peripheral blood mononuclear cells; PD-1: programmed cell death protein 1; RT-qPCR: reverse transcription quantitative polymerase chain reaction; sgRNA: single-guide RNA; Tc: cytotoxic T cells; Th: helper T cells; TIM-3:","cbCaikzGTRNVAXf9","https://ap.wps.com/l/cbCaikzGTRNVAXf9","pdf",1132033,13,"English","# Introduction\n## T cell exhaustion and catecholamine signaling\n# Methods\n## In vitro activation and pharmacologic treatments\n## Exhaustion assays and cytotoxicity co-culture\n## ADRB2 disruption using CRISPR/Cas9\n# Results\n## Nebivolol decreases exhaustion markers\n## Nebivolol enhances TNF and cytotoxicity against MCF-7\n## β2-AR dependency confirmed by ADRB2 disruption\n# Discussion\n## Reinvigoration of CD4+ and CD8+ T cells and implications","[{\"question\":\"How does nebivolol affect T cell exhaustion markers?\",\"answer\":\"Nebivolol reduces TIM-3+CD38+ PD-1+ T cells, downregulates TOX and nuclear NFATc1, and restores ADRB2 expression under repeated activation conditions.\"},{\"question\":\"Does nebivolol improve cytotoxicity against MCF-7 breast cancer cells?\",\"answer\":\"Yes. Nebivolol increases TNF secretion and improves cytotoxicity against MCF-7 cells in co-culture assays after repeated activation.\"},{\"question\":\"Is nebivolol’s effect dependent on β1- or β2-adrenergic receptors?\",\"answer\":\"The effects are mediated through β2-AR. Metoprolol (β1-blocker) does not inhibit nebivolol’s activity, and CRISPR/Cas9 disruption of ADRB2 indicates β2-AR dependency.\"}]","Nebivolol prevents exhausted T cells and enhances cytotoxicity against MCF-7 breast cancer cells in a β2-adrenergic receptor-dependent manner | PDF",1790094324,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3bbceb26d49984ba85bbc974791950f0.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0772e7aa2b391fd71dc198c27be352cf.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/898f960a1c7119f17a7c93ba52f67d38.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/384c43400eb62a3671bae9ee466d6114.webp",980,1287]